Meeting NewsVideo

VIDEO: Edible colon prep advances to phase 2b development

ORLANDO — In this exclusive video from the World Congress of Gastroenterology at ACG 2017, Corey A. Siegel, MD, MS, associate professor of medicine and director of the Inflammatory Bowel Disease Center at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, discusses the next steps for development of an edible colon prep product for colonoscopy.

“It was 1 year ago that Dr. Doug Rex presented our phase 2 results for this novel colon preparation called ECP, where we developed a series of edible bars and shakes that patients could use in preparation for colonoscopy instead of taking large volume, foul tasting liquids, to make their experience much easier and much more tolerable,” Siegel told Healio Gastroenterology and Liver Disease. “A year ago, Dr. Rex showed that this ECP product worked just as well if not better than comparator colon preparations, with a much higher tolerance by the patient population.”

The company developing this product, ColonaryConcepts, in partnership with Sebela Pharmaceuticals, recently announced a phase 2b study will begin this quarter, with a phase 3 study planned for the first half of next year, with the goal of bringing the product to market in 2020.

Disclosures: Siegel is a co-founder of ColonaryConcepts, a patent- and stockholder for an IBD risk prediction model, and reports financial relationships with AbbVie, American Regent, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Takeda and UCB.

ORLANDO — In this exclusive video from the World Congress of Gastroenterology at ACG 2017, Corey A. Siegel, MD, MS, associate professor of medicine and director of the Inflammatory Bowel Disease Center at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, discusses the next steps for development of an edible colon prep product for colonoscopy.

“It was 1 year ago that Dr. Doug Rex presented our phase 2 results for this novel colon preparation called ECP, where we developed a series of edible bars and shakes that patients could use in preparation for colonoscopy instead of taking large volume, foul tasting liquids, to make their experience much easier and much more tolerable,” Siegel told Healio Gastroenterology and Liver Disease. “A year ago, Dr. Rex showed that this ECP product worked just as well if not better than comparator colon preparations, with a much higher tolerance by the patient population.”

The company developing this product, ColonaryConcepts, in partnership with Sebela Pharmaceuticals, recently announced a phase 2b study will begin this quarter, with a phase 3 study planned for the first half of next year, with the goal of bringing the product to market in 2020.

Disclosures: Siegel is a co-founder of ColonaryConcepts, a patent- and stockholder for an IBD risk prediction model, and reports financial relationships with AbbVie, American Regent, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Takeda and UCB.

    See more from American College of Gastroenterology Annual Meeting